Sutro Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sutro Biopharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 51% in 3 years, but profit fell: $207 less profit per $100 of extra sales. Lower than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-52.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 73% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$207Sales grew 51% in 3 years, but profit fell: $207 less profit per $100 of extra sales.
Lower than 91% of Healthcare companies in United States.
Asset Productivity Ratio
+51% / -57%In 3 years sales changed by +51% while total assets changed by -57%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-22.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 57% of Healthcare companies in United States.
Cash Cushion Ratio
+74%Cash, after subtracting all debt, equals 74% of its market value (net cash).
Higher than 84% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Sutro Biopharma, Inc. made a loss over the last year. Sutro Biopharma, Inc. owes $1.53 for every $1 it owns. Sutro Biopharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSutro Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.50Sutro Biopharma, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$155 MThe total market value of all of Sutro Biopharma, Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeSutro Biopharma, Inc.'s net worth is negative ($103 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.53×Sutro Biopharma, Inc. owes $1.53 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneSutro Biopharma, Inc. does not currently pay a dividend.
Revenue growth
+65%Revenue rose 65% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Profit growth
LossSutro Biopharma, Inc. made a loss in each of the last two years.
Profit margin
-186.5%Sutro Biopharma, Inc. lost $186 for every $100 of revenue.
Interest cover
Not coveredSutro Biopharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSutro Biopharma, Inc. held $126 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Sutro Biopharma, Inc. owe compared with what it owns?
Sutro Biopharma, Inc. owes $1.53 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does Sutro Biopharma, Inc. pay a dividend?
No. Sutro Biopharma, Inc. does not currently pay a dividend.
Is Sutro Biopharma, Inc.'s revenue growing?
Revenue rose 65% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.